Full-Time

Field Reimbursement Manager

Updated on 7/22/2026

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

No salary listed

New Orleans, LA, USA + 1 more

More locations: Memphis, TN, USA

Remote

Category
Business & Strategy (1)
Required Skills
Data Analysis

Get referred to Mallinckrodt

Find people who can refer or advise you

Requirements
  • BS or equivalent, MBA or advanced degree ideal.
  • 5-7 years of relevant experience.
  • Previous experience managing customer interactions.
Responsibilities
  • Provider Account Support: Critical point person for all reimbursement and acquisition logistical aspects of a high touch biologic medication for an orphan disease, and testosterone products with multiple acquisition options within a changing payer landscape.
  • Assists HCP offices with questions related to Buy/Bill BI management. Educate/Assist with Specialty Pharmacy understanding, expectations and logistics. Continually educate office staff on appropriate steps, educate on the importance of chart documentation, keep offices up to date on payer policies for KEENOVA products and triage issues to the appropriate HUB and Specialty Pharmacy
  • Primary responsibilities include:
  • Managing patient assistance and reimbursement support services offered to providers and related to patient access to buy/bill products.
  • Coordinating with Keenova’s patient support services program representatives.
  • Educating office staff on the use of Buy/Bill products patient assistance and reimbursement support services.
  • Participating in sales training related to product reimbursement.
  • Utilizing data to critically think through acquisition challenges from a variety of outlets including Specialty Pharmacies, Specialty Distributors and Title sales.
  • Assist new offices from a reimbursement perspective to inform them about reimbursement issues as well as education on various MARC approved resources pertaining to reimbursement, acquisition and coding.
Desired Qualifications
  • Previous experience working with vendor relationships desirable.
  • Previous sales management and/or account management experience highly desirable.
  • Hands–on operational reimbursement experience – in-house and outsourced experience desirable.

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Get referred to Mallinckrodt

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.